Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review [BICR] per modified Response Assessment in Neuro-Oncology [RANO] 2.0), and are not in need of immediate chemotherapy or radiotherapy.
研究概览
地位
条件
干预/治疗
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Clinical Trials at Nuvation Bio
- 电话号码:332-208-6102
- 邮箱:ClinicalTrials@nuvationbio.com
学习地点
-
-
California
-
Los Angeles、California、美国、90095
- 尚未招聘
- University of California, Los Angeles
-
首席研究员:
- Robert Chong, MD
-
接触:
- Quan Li
- 电话号码:310-825-1416
- 邮箱:quanli@mednet.ucla.edu
-
San Francisco、California、美国、94143
- 尚未招聘
- University of California, San Francisco
-
首席研究员:
- John De Groot, MD
-
接触:
- Neuro Onc New Patient Coordinator
- 电话号码:415-353-2193
- 邮箱:neurooncnewpatientcoord@ucsf.edu
-
-
Connecticut
-
New Haven、Connecticut、美国、06510
- 尚未招聘
- Yale University
-
首席研究员:
- Nicholas Blondin, MD
-
接触:
- Amy Rodrigues
- 邮箱:amy.rodrigues@yale.edu
-
接触:
-
-
Florida
-
Miami、Florida、美国、33136
- 尚未招聘
- University of Miami Health
-
接触:
- Leonela Wright
- 电话号码:305-243-0864
- 邮箱:lxw612@med.miami.edu
-
首席研究员:
- Juan Blaquier, MD
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- 招聘中
- Indiana University
-
首席研究员:
- Kathryn Nevel, MD
-
接触:
- NeuroOncology Clinical Trials
- 电话号码:3179634823
- 邮箱:neuroct@iu.edu
-
-
Louisiana
-
New Orleans、Louisiana、美国、70112
- 尚未招聘
- LSU LCMC Health Cancer Center
-
首席研究员:
- Yazmin Odia, MD
-
接触:
- Yazmin Odia
- 电话号码:(646) 634-9655
- 邮箱:yodia@lsuhsc.edu
-
-
Massachusetts
-
Boston、Massachusetts、美国、02214
- 尚未招聘
- Massachusetts General Hospital
-
接触:
- Vihang Nakhate
- 电话号码:617-724-8770
- 邮箱:vnakhate@mgh.harvard.edu
-
首席研究员:
- Vihang Nakhate, MD
-
-
New Jersey
-
New Brunswick、New Jersey、美国、08901
- 尚未招聘
- Rutgers Cancer Institute
-
首席研究员:
- Morana Vojnic, MD
-
接触:
- Kasie Diorio
- 电话号码:732-235-2465
- 邮箱:kassie.diorio@rutgers.edu
-
-
New York
-
New York、New York、美国、10016
- 招聘中
- NYU Langone Health
-
接触:
- Jose McFaline-Figueroa, MD
- 电话号码:212-731-6267
- 邮箱:Jose.McFalineFigueroa@nyulangone.org
-
New York、New York、美国、10032
- 尚未招聘
- Columbia University Medical Center
-
首席研究员:
- Andrew Lassman, MD
-
接触:
- Research Nurse Navigator
- 电话号码:212-342-5162
- 邮箱:Cancerclinicaltrials@cumc.columbia.edu
-
-
Ohio
-
Cleveland、Ohio、美国、44106
- 尚未招聘
- Cleveland Clinic
-
首席研究员:
- Mina Lobbous, MD
-
接触:
- Marci Ciolfi
- 电话号码:216-445-3307
- 邮箱:ciolfim@ccf.org
-
Columbus、Ohio、美国、43210
- 尚未招聘
- The Ohio State University Comprehensive Cancer Center
-
接触:
- Pierre Giglio
- 电话号码:614-293-4448
- 邮箱:Pierre.Giglio@osumc.edu
-
首席研究员:
- Pierre Giglio, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1p19q co-deleted oligodendroglioma, according to WHO CNS 2021 criteria
- IDH1 mutation (e.g., R132H/C/G/S/L) based on immunohistochemistry (IHC) (R132H only), PCR, or next generation sequencing (NGS).
- Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection).
- Measurable disease per modified RANO 2.0 confirmed by BICR during Screening.
- Previously treated with vorasidenib and experienced radiographic disease progression during treatment and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator. Disease progression must be confirmed by BICR using modified RANO 2.0.
- Adequate hematologic and organ function
- Expected survival of ≥12 months
Key Exclusion Criteria:
- Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) and vorasidenib for treatment of glioma.
- Discontinued vorasidenib for toxicity or any reason other than radiographic disease progression
- Prior treatment with anti-angiogenic agents such as Avastin (bevacizumab) or investigational agents for glioma.
- Brainstem or spinal cord involvement either as primary location, site of multifocal involvement, or by significant tumor extension.
- Significant functional or neurocognitive deficits, including uncontrolled seizures
- Evidence of leptomeningeal disease.
- Use of therapeutic doses of steroids for signs/symptoms of glioma. Participants taking physiologic doses (defined as equivalent of <1.5 mg of dexamethasone equivalent) for medical conditions not related to glioma will be permitted.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Safusidenib
Safusidenib 250 mg BID |
Safusidenib administered twice daily as a single agent orally on Days 1 to 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)
大体时间:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
ORR defined as the proportion of participants with the confirmed best overall response of Complete Response (CR), Partial Response (PR) or Minor Response (MR) per modified RANO 2.0, assessed by BICR |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
ORR per modified RANO 2.0 assessed by Investigator
大体时间:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
ORR defined as the proportion of participants with the confirmed best overall response of CR, PR or MR per modified RANO 2.0, assessed by the Investigator |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Volumetric Tumor Growth Rate (TGR) by BICR
大体时间:From historical scans through the final scan in the study, approximately 18 months
|
TGR defined as the percentage change in tumor volume by unit of time, assessed by BICR |
From historical scans through the final scan in the study, approximately 18 months
|
|
Duration of Response (DOR) per modified RANO 2.0 assessed by BICR and by Investigator
大体时间:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
DOR, time from the first documentation of objective response (CR, PR, or MR) to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier. |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Time to Next Intervention (TTNI)
大体时间:From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
|
TTNI, defined as the time from the first dose of study drug to the initiation of first subsequent anticancer therapy or death from any cause, whichever occurs earlier |
From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
|
|
Progression Free Survival (PFS) per modified RANO 2.0 assessed by BICR and by Investigator
大体时间:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
PFS, defined as the time from the first dose of study drug to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier. |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Time to Response (TTR) per modified RANO 2.0 assessed by BICR and by Investigator
大体时间:From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
|
TTR, defined as the time from the first dose of study drug to the first documentation of objective response (CR, PR, or MR) per modified RANO 2.0, assessed by BICR and by the Investigator |
From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
|
|
Overall Survival (OS)
大体时间:From the date of first dose of study drug until the date of death, approximately 18 months
|
OS, defined as the time from the first dose of study drug to death from any cause. |
From the date of first dose of study drug until the date of death, approximately 18 months
|
|
Safety and tolerability
大体时间:From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
|
The safety and tolerability of safusidenib evaluated based on AEs graded by NCI-CTCAE version 5.0, laboratory abnormalities as graded by NCI-CTCAE version 5.0, vital signs, physical examinations, and ECGs |
From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
|
|
Seizure Activity
大体时间:From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
Evaluate seizure frequencies and severity including type of seizure, seizure-related AEs, and changes in anti-epileptic medications in participants receiving safusidenib |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.